Article Details

Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist

Retrieved on: 2019-05-15 20:00:00

Tags for this article:

Click the tags to see associated articles and topics

Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist. View article details on hiswai:

Excerpt

<div>He previously was a partner at <b>New Enterprise Associates</b>, where he spent 15 years in commercial and operating leadership roles in the biotech and ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo